265 related articles for article (PubMed ID: 36587744)
41. Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity.
Breen WG; Young JR; Hathcock MA; Kowalchuk RO; Thorpe MP; Bansal R; Khurana A; Bennani NN; Paludo J; Bisneto JV; Wang Y; Ansell SM; Peterson JL; Johnston PB; Lester SC; Lin Y
Blood Cancer J; 2023 Aug; 13(1):127. PubMed ID: 37591834
[TBL] [Abstract][Full Text] [Related]
42. Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden.
Qu C; Ping N; Kang L; Liu H; Qin S; Wu Q; Chen X; Zhou M; Xia F; Ye A; Kong D; Li C; Yu L; Wu D; Jin Z
J Immunother; 2020 Jan; 43(1):32-37. PubMed ID: 31219975
[TBL] [Abstract][Full Text] [Related]
43. Low-Frequency
Seipel K; Frey M; Nilius H; Akhoundova D; Banz Y; Bacher U; Pabst T
Curr Oncol; 2023 Dec; 30(12):10463-10476. PubMed ID: 38132396
[TBL] [Abstract][Full Text] [Related]
44. Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell Lymphoma.
Sigmund AM; Denlinger N; Huang Y; Bond D; Voorhees T; Bajwa A; Elder P; Brammer JE; Saad A; Penza S; Vasu S; de Lima M; Jaglowski S; Kittai AS
Transplant Cell Ther; 2022 Jun; 28(6):342.e1-342.e5. PubMed ID: 35248778
[TBL] [Abstract][Full Text] [Related]
45. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
Cao Y; Xiao Y; Wang N; Wang G; Huang L; Hong Z; Meng L; Zhou X; Wang J; Yang Y; Xu H; Zhang S; Xiao M; Chen L; Zheng M; Li C; Mao X; Gu C; Zhang T; Zhang Y; Zhou J
Transplant Cell Ther; 2021 Nov; 27(11):910.e1-910.e11. PubMed ID: 34425260
[TBL] [Abstract][Full Text] [Related]
46. Prognostic impact of peripheral eosinophil counts in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy.
Dang X; Ye S; Zhou L; Lu Y; Li P; Liang A; Qian W
Cytotherapy; 2023 Jun; 25(6):573-577. PubMed ID: 36456447
[TBL] [Abstract][Full Text] [Related]
47. Adenovirus-induced hemorrhagic cystitis after CD19-targeted chimeric antigen receptor T-cell therapy in a patient with large B-cell lymphoma.
Medina I; Carpio C; Ruiz-Camps I; Albasanz-Puig A; Lopez-Godino O; Esperalba J; Beas F; Sanchez-Salinas M; Iacoboni G; Barba P
Immunotherapy; 2023 Nov; 15(16):1369-1374. PubMed ID: 37718888
[TBL] [Abstract][Full Text] [Related]
48. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X
Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088
[TBL] [Abstract][Full Text] [Related]
49. Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy.
Zhu W; Tao S; Miao W; Liu H; Yuan X
Front Immunol; 2022; 13():894787. PubMed ID: 35757723
[TBL] [Abstract][Full Text] [Related]
50. [Tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma: real-world data from single institute experience].
Yagi Y; Kanemasa Y; Sasaki Y; Hayashi Y; Mino M; Kato C; Sakai S; Ohigashi A; Kanbara Y; Morita Y; Tamura T; Atsuta Y; Konuma R; Nakamura S; Wada A; Okuya T; Kageyama A; Murakami D; Nakashima S; Uchibori Y; Onai D; Hamamura A; Nishijima A; Omuro Y; Shingai N; Shimizuguchi T; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Ohashi K; Doki N; Okuyama Y; Shimoyama T
Rinsho Ketsueki; 2022; 63(10):1363-1372. PubMed ID: 36351641
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
52. Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy.
Iacoboni G; Navarro V; Martín-López AÁ; Rejeski K; Kwon M; Jalowiec KA; Amat P; Reguera-Ortega JL; Gallur L; Blumenberg V; Gutiérrez-Herrero S; Roddie C; Benzaquén A; Delgado-Serrano J; Sánchez-Salinas MA; Bailén R; Carpio C; López-Corral L; Hernani R; Bastos M; O'Reilly M; Martín-Martín L; Subklewe M; Barba P
J Clin Oncol; 2024 Jan; 42(2):205-217. PubMed ID: 37874957
[TBL] [Abstract][Full Text] [Related]
53. Real-World Treatment Patterns After CD19-Directed CAR T Cell Therapy Among Patients with Diffuse Large B Cell Lymphoma.
Jalbert JJ; Wu N; Chen CI; Ambati S; Ge W; Arnason JE
Adv Ther; 2022 Jun; 39(6):2630-2640. PubMed ID: 35397110
[TBL] [Abstract][Full Text] [Related]
54. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.
Hirayama AV; Gauthier J; Hay KA; Voutsinas JM; Wu Q; Gooley T; Li D; Cherian S; Chen X; Pender BS; Hawkins RM; Vakil A; Steinmetz RN; Acharya UH; Cassaday RD; Chapuis AG; Dhawale TM; Hendrie PC; Kiem HP; Lynch RC; Ramos J; Shadman M; Till BG; Riddell SR; Maloney DG; Turtle CJ
Blood; 2019 Apr; 133(17):1876-1887. PubMed ID: 30782611
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of chimeric antigen receptor T cell therapy in relapsed/refractory diffuse large B-cell lymphoma with different HBV status: a retrospective study from a single center.
Kong D; Ping N; Gao X; Zou R; Wang P; Wu D; Jin Z; Qu C
Front Immunol; 2023; 14():1200748. PubMed ID: 37292195
[TBL] [Abstract][Full Text] [Related]
56. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study.
Epperla N; Feng L; Shah NN; Fitzgerald L; Shah H; Stephens DM; Lee CJ; Ollila T; Shouse G; Danilov AV; David KA; Torka P; Hashmi H; Hess B; Barta SK; Romancik JT; Cohen JB; Annunzio K; Kittai AS; Reneau J; Zurko J; Nizamuddin IA; Winter JN; Gordon LI; Ma S; Patel R; Nastoupil L; Ahmed S; Karmali R
J Hematol Oncol; 2023 Nov; 16(1):111. PubMed ID: 37946255
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burden.
Mu J; Deng H; Lyu C; Yuan J; Li Q; Wang J; Jiang Y; Deng Q; Shen J
Hematol Oncol; 2023 Apr; 41(2):275-284. PubMed ID: 35195933
[TBL] [Abstract][Full Text] [Related]
58. [Current and future perspectives on CAR-T cell therapy to adult malignant lymphoma].
Shimoyama T
Rinsho Ketsueki; 2023; 64(9):1192-1202. PubMed ID: 37899200
[TBL] [Abstract][Full Text] [Related]
59. The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy.
Garcia-Recio M; Wudhikarn K; Pennisi M; Alonso-Trillo R; Flynn J; Shouval R; Afuye AO; Silverberg ML; Batlevi CW; Dahi P; Devlin S; Giralt SA; Halton E; Ruiz J; Maloy M; Mead E; Palomba ML; Santomasso B; Sauter CS; Scordo M; Shah GL; Perales MA
Transplant Cell Ther; 2021 Mar; 27(3):233-240. PubMed ID: 33781518
[TBL] [Abstract][Full Text] [Related]
60. Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma.
Ghobadi A
Curr Res Transl Med; 2018 May; 66(2):43-49. PubMed ID: 29655961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
